


Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

| | |
|--------------------------|---|
| Product Name | : Ibrutinib |
| Cat. No. | : PC-42772 |
| CAS No. | : 936563-96-1 |
| Molecular Formula | : C ₂₅ H ₂₄ N ₆ O ₂ |
| Molecular Weight | : 440.4971 |
| Target | : BTK |
| Solubility | : DMSO: ≥ 52 mg/mL |



Biological Activity

Ibrutinib (PCI-32765, PCI32765) is a potent and highly selective, covalent **BTK** inhibitor with IC₅₀ of 0.5 nM. Ibrutinib modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib (PCI-32765) selectively inhibits B-cell signaling and activation. It inhibits autophosphorylation of Btk (IC₅₀=11 nM), phosphorylation of Btk's physiological substrate PLCγ (IC₅₀=29 nM). Ibrutinib (PCI-32765) inhibits BCR-activated primary B cell proliferation (IC₅₀=8 nM). Following FcγR stimulation, Ibrutinib (PCI-32765) inhibits TNFα, IL-1β and IL-6 production in primary monocytes (IC₅₀=2.6, 0.5, 3.9 nM, respectively). Ibrutinib (PCI-32765) (3.125-50 mg/kg, p.o.) reduces the level of circulating autoantibodies and completely suppresses disease in mice with collagen-induced arthritis. Ibrutinib (PCI-32765) (0.1 μM) inhibits activation-induced proliferation of CLL cells, induces selective cytotoxicity in B cells compared with T cells, but alters activation induced T-cell cytokine production.

References

- Honigberg LA, et al. *Proc Natl Acad Sci U S A*. 2010 Jul 20;107(29):13075-80.
 Herman SE, et al. *Blood*. 2014 May 22;123(21):3286-95.
 Kohrt HE, et al. *Blood*. 2014 Mar 20;123(12):1957-60.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com